Guillain-Barré syndrome

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Guillain-Barré syndrome (GBS) is the leading cause of acute paralytic neuropathy, characterized by distinct variants.
• While the precise cause remains unknown, GBS often follows infections (respiratory or gastrointestinal) or other immune stimuli, triggering an autoimmune response against peripheral nerves.
• The factors influencing the shift towards autoreactivity and individual susceptibility (genetic/environmental) are not fully understood.

Purpose of the Study:

• To review the clinical features and diagnostic criteria of GBS.
• To propose a management algorithm for GBS.
• To discuss recent advancements in understanding GBS etiopathogenesis and treatment strategies.

Main Methods:

• Literature analysis and review of existing studies on Guillain-Barré syndrome.
• Synthesis of information on clinical presentation, diagnosis, and management.
• Examination of emerging infectious triggers and their impact.

Main Results:

• GBS management requires meticulous monitoring, supportive care, and prompt specific treatment.
• Despite advances, current therapies are insufficient for many patients, particularly those with acute inflammatory demyelinating polyneuropathy.
• New post-infectious forms (e.g., Zika virus, enterovirus D68) necessitate further investigation.

Conclusions:

• Early diagnosis and treatment are vital for GBS patients.
• Ongoing research is needed to identify biomarkers for disease severity and methods to prevent axonal injury.
• Further analysis of novel post-infectious GBS variants is essential for improving patient outcomes.